Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More goodwill for gainsharing

This article was originally published in The Gray Sheet

Executive Summary

HHS Office of Inspector General has now awarded safe harbor to 12 hospitals to enact arrangements where physicians are financially rewarded for agreeing to implement a number of cost reduction activities. The latest advisory opinion exempting a gainsharing program from civil money penalty and anti-kickback enforcement, posted Oct. 14, addresses an unnamed hospital's cardiac catheterization laboratory. The proposed program is similar to others that OIG has approved in that it includes physician agreements to standardize products and limit use of certain products, while also including safeguards to prevent reductions in clinical quality. But it is the first multi-year program the office has approved. Previous arrangements were planned to extend for only one year (1"The Gray Sheet" Jan. 21, 2008, p. 15

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel